Market Context

Investing.com’s AI‑driven InvestingPro service highlighted a sharp rotation toward small‑cap value and defensive healthcare equities after a three‑day market decline. The article, dated 20‑08‑2026, promotes a subscription priced under $8 per month during a summer sale and claims that members have already captured large post‑earnings moves in stocks such as Mativ Holdings (NYSE:MATV) and Everforth (NYSE:EFOR).

Recent Performance of Highlighted Healthcare Stocks

During the last month, Bausch Health (NYSE:BHC) advanced 43.5%, Tenet Healthcare (NYSE:THC) rose 38.6% (41.13% since initially selected), and Haemonetics (NYSE:HAE) climbed 34.4% (98.75% since selection). Everforth posted a 64.4% gain for the month and an 81.95% increase since it was first added to the AI model in July, while still trading approximately 57.8% below the fair‑value estimate supplied by InvestingPro’s valuation aggregation.

Bausch Health Q2 Results and Guidance

Bausch Health reported second‑quarter revenue of $2.85 billion, marking its 13th consecutive quarter of top‑ and bottom‑line growth. Non‑GAAP earnings per share jumped to $1.26, comfortably beating the consensus estimate of $1.01. Management subsequently raised its full‑year revenue guidance to a range of $10.7 billion to $11.04 billion and projected EBITDA of $4.175 billion. The company also highlighted a 21% surge in Xifaxan sales and a 51% increase in Solta Medical revenue, while its share price trades at roughly 12 times adjusted earnings and about 34% below analyst fair‑value targets (average $7.57, InvestingPro’s $8.51).

AI Model Rationale for Bausch Health

The proprietary machine‑learning engine identified Bausch Health based on four quantitative signals: (1) twelve consecutive quarters of top‑line expansion, with Q1 2026 revenue up roughly 12% to $2.52 billion and adjusted EBITDA up 27% year‑over‑year; (2) strong segment momentum, notably the 21% rise in Xifaxan and 51% jump in Solta Medical; (3) an attractive valuation of about 12 times adjusted earnings and a 34% discount to fair‑value estimates; and (4) an improving risk‑reward profile reflected by declining debt levels and key litigation settlements that de‑risked the balance sheet. Early‑year guidance reaffirmations further reinforced model conviction before the official upgrade to the $10.7‑$11.04 billion revenue target.

Additional Long‑Term Winners Since Model Launch

Beyond the healthcare names, the AI system has identified other high‑conviction stocks that have delivered substantial returns since their initial selection: Consensus Cloud Solutions (NASDAQGS:CCSI) is up 78.46%, Delek US Energy (NYSE:DK) has risen 76.19%, and Nucor (NYSE:NUE) gained 56.23%.

Cumulative Performance of the AI‑Powered Strategy

Since the AI models were launched in November 2023, InvestingPro’s AI‑driven stock picks have generated a cumulative return of +193.62%, outperforming the S&P 500 by an additional 111.65% over the same period.

Subscription Offer and Access

The article repeatedly invites readers to subscribe via app or web, emphasizing a discount of up to 55% during the summer promotion. Subscribers gain access to the full August list of AI‑selected stocks, detailed rationales, and fair‑value calculations that aggregate 17 institutional‑grade valuation models.

How the AI Stock Picker Operates

Each month, the proprietary AI engine evaluates thousands of global equities using a blend of historical financial data, valuation signals, and forward‑looking growth metrics. It processes more than 15 years of data across over 150 quantitative models to select up to 20 high‑conviction stocks per strategy. The selected basket is equally weighted, rebalanced monthly, and serves as a transparent benchmark for performance evaluation.

---